Teva Pharmaceutical Industries reported $4.08B in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Aspen Pharmacare ZAR 16B 10.38B Jun/2026
Cipla INR 16.59B 6.41B Sep/2026
Dr.Reddys Laboratories INR 11.2B 4.16B Jun/2026
Guangzhou Baiy CNY 13.29B 961.66M Jun/2026
Jiangsu Hengrui CNY 43.45B 4.71B Sep/2026
Kalbe Farma IDR 4.83T 439.13B Jun/2026
Richter Gedeon HUF 135.63B 61.59B Dec/2024
Sh Fosun Pharma CNY 13.3B 230.95M Sep/2026
Sun Pharmaceuticals INR 97.71B 15.61B Mar/2026
Teva Pharmaceutical Industries USD 4.08B 430M Sep/2026